Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07068074 · ClinicalTrials.gov registry record · Phase 3
A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Not yet
- Registry status
- Phase 3
- Development phase
- 428
- Enrollment target
NCT07068074: Clinical Trial Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
NCT07068074 is a Phase 3 study that has not yet begun recruiting, run by Eastern Cooperative Oncology Group. The registered enrollment target is 428 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07068074, a Phase 3 study, has not yet begun recruiting, sponsored by Eastern Cooperative Oncology Group.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 428 participants
- Enrollment target
Study Summary
Can we treat your melanoma just as effectively without doing a sentinel lymph node (SLN) biopsy in addition to your wide local excision (WLE) procedure? A wide local excision (WLE) is a surgical procedure performed to cut out an abnormal lesion and some surrounding normal tissue. This is sometimes followed by a sentinel lymph node (SLN) biopsy, in which lymph nodes that cancer cells could spread to are removed as well. We are doing this study because we want to find out if performing the WLE alone is just as effective as the usual approach for your melanoma, and if it leads to improvements in patients' overall well-being. The usual approach is defined as care most people get for the early stage of melanoma that you currently have.
Primary Outcome
The patient reported outcomes (PRO) in this study include a Geriatric Assessment (GA) and the FACT-M Quality of Life (QOL). The National Comprehensive Cancer Network (NCCN) guidelines advocate geriatric assessment (GA) for older patients with cancer to identify health status issues that increase the risk of adverse outcomes. A GA evaluates comorbidity, functional status, physical performance, cognitive ability, psychological status, medications and social support with standardized tools that pre
Interventions
- PROCEDURE Wide local Excision
- PROCEDURE Sentinel Lymph Node and Wide Local Excision
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2031-01-01 |
| Phase | Phase 3 |
What is known before NCT07068074 opens enrollment
NCT07068074 is an interventional study that assigns participants to a tested intervention. The registered 428 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 2 interventions - of which Wide local Excision is the first listed.
NCT07068074 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07068074 about?
NCT07068074 is a clinical study titled "A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients". Can we treat your melanoma just as effectively without doing a sentinel lymph node (SLN) biopsy in addition to your wide local excision (WLE) procedure? A wide local excision (WLE) is a surgical procedure performed to cut out an abnormal lesion and some surrounding normal tissue. This is sometimes f...
What is the current status of trial NCT07068074?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 428 participants. The study started on 2025-12-12. Estimated completion is 2031-01-01.
What interventions are being tested in trial NCT07068074?
The interventions under investigation include: Wide local Excision (PROCEDURE), Sentinel Lymph Node and Wide Local Excision (PROCEDURE).
Who is sponsoring clinical trial NCT07068074?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07068074's enrollment target sits among peer trials
428 878th of 2000 higher than 1,121 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05566431 · 428 participants · NA
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
- NCT05646316 · 428 participants · Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- NCT05797610 · 428 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- NCT06073626 · 428 participants · NA
Addressing Genomic Disparities in Cancer Survivors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI